Novartis Ag (NVS)

$106.13

-1.09

(-1.02%)

Market is closed - opens 7 PM, 22 Jul 2024
star icon

Novartis AG is a multinational pharmaceutical company that produces and markets innovative medicines, eye care products, and generics.

Performance

  • $105.73
    $106.49
    $106.13
    downward going graph

    0.38%

    Downside

    Day's Volatility :0.71%

    Upside

    0.34%

    downward going graph
  • $88.80
    $112.48
    $106.13
    downward going graph

    16.33%

    Downside

    52 Weeks Volatility :21.05%

    Upside

    5.65%

    downward going graph

Returns

PeriodNovartis AgSector (Health Care)Index (Russel 2000)
3 Months
11.57%
6.4%
0.0%
6 Months
-2.16%
6.0%
0.0%
1 Year
0.95%
9.6%
0.0%
3 Years
17.61%
14.8%
-19.4%

Highlights

Market Capitalization
217.9B
Book Value
$19.45
Dividend Share
3.919
Dividend Yield
3.52%
Earnings Per Share (EPS)
4.89
PE Ratio
21.73
PEG Ratio
5.09
Wall Street Target Price
113.46
Profit Margin
31.94%
Operating Margin TTM
30.78%
Return On Assets TTM
8.65%
Return On Equity TTM
19.83%
Revenue TTM
47.7B
Revenue Per Share TTM
23.17
Quarterly Revenue Growth YOY
9.700000000000001%
Gross Profit TTM
36.7B
EBITDA
18.9B
Diluted Eps TTM
4.89
Quarterly Earnings Growth YOY
0.22
EPS Estimate Current Year
7.34
EPS Estimate Next Year
8.12
EPS Estimate Current Quarter
1.67
EPS Estimate Next Quarter
1.81

Analyst Recommendation

Buy
    50%Buy
    43%Hold
    6%Sell
Based on 32 Wall street analysts offering stock ratings for Novartis Ag(by analysts ranked 0 to 5 stars)
Based on 32 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
15
17
Hold
14
14
13
Sell
2
2
2

Analyst Forecast

What analysts predicted

Upside of 6.91%

Current $106.13
Target $113.46

Company Financials

FY18Y/Y Change
Revenue
53.2B
↑ 6.05%
Net Income
12.6B
↑ 63.72%
Net Profit Margin
23.72%
↑ 8.36%
FY19Y/Y Change
Revenue
48.7B
↓ 8.44%
Net Income
7.1B
↓ 43.33%
Net Profit Margin
14.68%
↓ 9.04%
FY20Y/Y Change
Revenue
49.9B
↑ 2.51%
Net Income
8.1B
↑ 12.94%
Net Profit Margin
16.18%
↑ 1.5%
FY21Y/Y Change
Revenue
52.9B
↑ 5.97%
Net Income
24.0B
↑ 197.58%
Net Profit Margin
45.43%
↑ 29.25%
FY22Y/Y Change
Revenue
51.8B
↓ 1.98%
Net Income
7.0B
↓ 71.05%
Net Profit Margin
13.42%
↓ 32.01%
FY23Y/Y Change
Revenue
46.7B
↓ 9.97%
Net Income
14.9B
↑ 113.52%
Net Profit Margin
31.83%
↑ 18.41%
Q4 FY22Q/Q Change
Revenue
13.1B
↑ 1.91%
Net Income
1.5B
↓ 6.8%
Net Profit Margin
11.2%
↓ 1.05%
Q1 FY23Q/Q Change
Revenue
13.2B
↑ 0.92%
Net Income
2.3B
↑ 56.41%
Net Profit Margin
17.36%
↑ 6.16%
Q2 FY23Q/Q Change
Revenue
13.9B
↑ 5.51%
Net Income
2.3B
↑ 1.0%
Net Profit Margin
16.62%
↓ 0.74%
Q3 FY23Q/Q Change
Revenue
12.1B
↓ 13.23%
Net Income
1.8B
↓ 23.96%
Net Profit Margin
14.56%
↓ 2.06%
Q4 FY23Q/Q Change
Revenue
11.8B
↓ 2.61%
Net Income
8.5B
↑ 381.54%
Net Profit Margin
72.01%
↑ 57.45%
Q1 FY24Q/Q Change
Revenue
11.8B
↑ 0.45%
Net Income
2.7B
↓ 68.3%
Net Profit Margin
22.72%
↓ 49.29%
FY18Y/Y Change
Total Assets
145.6B
↑ 9.38%
Total Liabilities
66.9B
↑ 13.63%
FY19Y/Y Change
Total Assets
118.4B
↓ 18.68%
Total Liabilities
62.8B
↓ 6.06%
FY20Y/Y Change
Total Assets
132.1B
↑ 11.56%
Total Liabilities
75.4B
↑ 20.02%
FY21Y/Y Change
Total Assets
131.8B
↓ 0.2%
Total Liabilities
64.0B
↓ 15.15%
FY22Y/Y Change
Total Assets
117.5B
↓ 10.88%
Total Liabilities
58.0B
↓ 9.29%
FY23Y/Y Change
Total Assets
99.9B
↓ 14.91%
Total Liabilities
53.2B
↓ 8.33%
Q4 FY22Q/Q Change
Total Assets
117.5B
↓ 0.85%
Total Liabilities
58.0B
↑ 0.81%
Q1 FY23Q/Q Change
Total Assets
112.2B
↓ 4.44%
Total Liabilities
60.1B
↑ 3.57%
Q2 FY23Q/Q Change
Total Assets
111.0B
↓ 1.12%
Total Liabilities
59.0B
↓ 1.75%
Q3 FY23Q/Q Change
Total Assets
112.7B
↑ 1.55%
Total Liabilities
74.5B
↑ 26.09%
Q4 FY23Q/Q Change
Total Assets
99.9B
↓ 11.32%
Total Liabilities
53.2B
↓ 28.55%
Q1 FY24Q/Q Change
Total Assets
94.3B
↓ 5.61%
Total Liabilities
54.6B
↑ 2.6%
FY18Y/Y Change
Operating Cash Flow
14.3B
↑ 13.08%
Investing Cash Flow
-5.6B
↑ 79.26%
Financing Cash Flow
-4.2B
↓ 45.12%
FY19Y/Y Change
Operating Cash Flow
13.6B
↓ 4.53%
Investing Cash Flow
-2.2B
↓ 60.19%
Financing Cash Flow
-13.6B
↑ 221.09%
FY20Y/Y Change
Operating Cash Flow
13.7B
↑ 0.18%
Investing Cash Flow
-13.2B
↑ 492.18%
Financing Cash Flow
-2.2B
↓ 83.8%
FY21Y/Y Change
Operating Cash Flow
15.1B
↑ 10.41%
Investing Cash Flow
4.2B
↓ 131.92%
Financing Cash Flow
-16.3B
↑ 636.59%
FY22Y/Y Change
Operating Cash Flow
14.2B
↓ 5.54%
Investing Cash Flow
1.5B
↓ 65.11%
Financing Cash Flow
-20.6B
↑ 26.43%
FY23Y/Y Change
Operating Cash Flow
14.5B
↑ 1.56%
Investing Cash Flow
5.6B
↑ 281.2%
Financing Cash Flow
-14.3B
↓ 30.56%
Q4 FY22Q/Q Change
Operating Cash Flow
4.1B
↓ 12.92%
Investing Cash Flow
1.5B
↓ 71.76%
Financing Cash Flow
-4.0B
↓ 15.7%
Q1 FY23Q/Q Change
Operating Cash Flow
3.0B
↓ 28.07%
Investing Cash Flow
10.6B
↑ 623.5%
Financing Cash Flow
-9.2B
↑ 130.4%
Q2 FY23Q/Q Change
Operating Cash Flow
3.6B
↑ 20.93%
Investing Cash Flow
-1.1B
↓ 109.91%
Financing Cash Flow
-3.6B
↓ 60.48%
Q3 FY23Q/Q Change
Operating Cash Flow
5.4B
↑ 50.39%
Investing Cash Flow
-2.2B
↑ 110.07%
Financing Cash Flow
-832.0M
↓ 77.12%
Q4 FY23Q/Q Change
Operating Cash Flow
2.5B
↓ 52.64%
Investing Cash Flow
-1.8B
↓ 20.43%
Financing Cash Flow
-607.0M
↓ 27.04%
Q1 FY24Q/Q Change
Operating Cash Flow
2.3B
↓ 11.07%
Investing Cash Flow
-899.0M
↓ 48.92%
Financing Cash Flow
-5.2B
↑ 750.74%

Technicals Summary

Sell

Neutral

Buy

Novartis Ag is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Novartis Ag
Novartis Ag
0.37%
-2.16%
0.95%
17.61%
12.86%
Eli Lilly And Company
Eli Lilly And Company
-3.22%
35.92%
84.87%
264.85%
699.36%
Johnson & Johnson
Johnson & Johnson
4.68%
-4.79%
-8.13%
-8.17%
20.25%
Merck & Co. Inc.
Merck & Co. Inc.
-3.01%
5.31%
15.96%
65.12%
54.87%
Abbvie Inc
Abbvie Inc
0.11%
4.19%
21.19%
48.49%
153.41%
Amgen Inc.
Amgen Inc.
6.91%
6.81%
42.04%
34.19%
88.35%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Novartis Ag
Novartis Ag
21.73
21.73
5.09
7.34
0.2
0.09
0.04
19.45
Eli Lilly And Company
Eli Lilly And Company
138.88
138.88
1.43
13.76
0.51
0.13
0.01
14.23
Johnson & Johnson
Johnson & Johnson
23.76
23.76
0.89
10.03
0.24
0.08
0.03
28.57
Merck & Co. Inc.
Merck & Co. Inc.
139.61
139.61
0.1
8.14
0.05
0.1
0.02
15.94
Abbvie Inc
Abbvie Inc
51.27
51.27
0.45
9.83
0.56
0.08
0.04
4.54
Amgen Inc.
Amgen Inc.
47.42
47.42
2.39
19.48
0.73
0.05
0.03
9.36
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Novartis Ag
Novartis Ag
Buy
$217.9B
12.86%
21.73
31.94%
Eli Lilly And Company
Eli Lilly And Company
Buy
$847.8B
699.36%
138.88
17.08%
Johnson & Johnson
Johnson & Johnson
Buy
$374.0B
20.25%
23.76
44.92%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$314.7B
54.87%
139.61
3.76%
Abbvie Inc
Abbvie Inc
Buy
$303.3B
153.41%
51.27
11.02%
Amgen Inc.
Amgen Inc.
Buy
$177.5B
88.35%
47.42
12.74%

Insights on Novartis Ag

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 11.77B → 11.82B (in $), with an average increase of 0.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 8.48B → 2.68B (in $), with an average decrease of 68.3% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 84.9% return, outperforming this stock by 83.9%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 264.8% return, outperforming this stock by 247.2%

Institutional Holdings

  • PRIMECAP Management Company

    0.61%
  • Dodge & Cox

    0.61%
  • Morgan Stanley - Brokerage Accounts

    0.36%
  • Dimensional Fund Advisors, Inc.

    0.29%
  • Loomis, Sayles & Company LP

    0.29%
  • Franklin Resources Inc

    0.28%

Corporate Announcements

  • Novartis Ag Dividends March,2024

    In the quarter ending March,2024. Novartis Ag has declared dividend of $3.78

    Read More

Company Information

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

Organization
Novartis Ag
Employees
76057
CEO
Dr. Vasant Narasimhan M.D.
Industry
Health Technology

FAQs